AADI Company Profile and Key Details

AADI has shown mixed momentum, gaining 6.22% over the past week and -14.94% over the past quarter, though year-to-date performance is down -35.13%. Short-term trend indicators are mixed aligned (SMA20 -11.89%, SMA50 -24.67%, SMA200 -3.13%). The stock’s 14-day RSI is 35.66 (weak momentum), while the ATR of 0.17 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -46.22% below its high and over 69.42% above its low.

Aadi Bioscience, Inc. generated EPS of -$2.29 over the past year. Five-year average earnings growth is 11.87%. Wall Street analysts project EPS growth of 20.18% annually over the next five years. The latest quarter delivered EPS of -$0.67. The next quarter is forecast at -$0.35. Next year's EPS is expected at -$7.34. Aadi Bioscience, Inc. earnings surprise history is a mixed track record. The quarter that ended March 18, 2025, missed forecasts by 123.33%. The prior quarter beat by 0.86%. Over the last six quarters, Apple has recorded several small beats. These include -17.81% in November 08, 2023.

Aadi Bioscience, Inc. has 46.29 million shares outstanding. The public float is 8.31 million shares, elevated short interest at 7.23% of float. This equals 793.92 thousand shares. The short ratio is 8.87 days. Institutional investors hold 53.27% of the float. Insiders own 6.1%. Satter Muneer A holds 5.62 million shares, Khuong Chau Quang has 5.19 million shares and Novartis Bioventures Ltd has 4.05 million shares.

Aadi Bioscience, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.14. This means the shares are trading below this model’s fair value.

Aadi Bioscience, Inc. (NASDAQ:AADI) closed at $2.05 USD, losing -$0.05 (-2.38%) from the previous close of $2.10. The stock is currently mid-range between its 52-week high and low $1.21 and $3.81. With a market capitalization of about $94.89 million, Aadi Bioscience, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.34). Key stats such as the average daily volume over the past year has been around 200.71 thousand shares, volume is running light vs its 52-week average. Headquartered in Pacific Palisades, CA, Aadi Bioscience, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David J. Lennon, the company employs approximately 53 people and listed since February 16, 2018. Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing highly targeted therapies for cancers defined by specific genetic alterations within the mTOR pathway.

Our AI price prediction model suggests that Aadi Bioscience, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -20.0%, with price expected at $1.52 by April 10, 2025, within a range of $1.33 to $1.69 3-Month Outlook: Projected rise of 124.21%, reaching $4.26 by June 17, 2025, with a range of $4.14 to $4.40. 1-Year Outlook: Projected gain of 438.42%, with price at $10.23 by March 20, 2026, within a range of $4.87 to $12.33.

Aadi Bioscience, Inc. (NASDAQ:AADI) shares are down -35.13% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Aadi Bioscience, Inc. trading at a premium to the broader market with a P/E of -1.49. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $40.34, suggesting 2023.16% upside. Our AI forecast model points to short-term weakness (-20.0% over two weeks), a medium-term rise (124.21% over three months), and a longer-term gain (438.42% over one year), with expected trading ranges indicating moderate volatility.

Aadi Bioscience, Inc. trades at a P/E ratio of -1.49, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.22 suggesting the stock is closer to book value. The P/FCF stands at -9.69, also below market averages.